AR083693A1 - Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit - Google Patents

Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit

Info

Publication number
AR083693A1
AR083693A1 ARP110104077A ARP110104077A AR083693A1 AR 083693 A1 AR083693 A1 AR 083693A1 AR P110104077 A ARP110104077 A AR P110104077A AR P110104077 A ARP110104077 A AR P110104077A AR 083693 A1 AR083693 A1 AR 083693A1
Authority
AR
Argentina
Prior art keywords
inhibitor
formulation
cholesterile
kit
tablet
Prior art date
Application number
ARP110104077A
Other languages
English (en)
Inventor
Michaela Krabichler
Bernard Meyer
Carsten Winzenburg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR083693A1 publication Critical patent/AR083693A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Formulación basada en una matriz higroscópica, un proceso para la fabricación de la misma y su utilización para el tratamiento de enfermedades.Reivindicación 1: Una composición que contiene: a) 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil]amino)fenilo] y b) croscarmelosa sódica. Reivindicación 15: Una composición según una cualquiera de las reivindicaciones de 1 a 11, en la que hay por lo menos un 30% en peso de excipientes poliméricos higroscópicos. Reivindicación 22: Una composición según una cualquiera de las reivindicaciones de 2 a 21, cuyos excipientes poliméricos higroscópicos son la hidroxipropilmetilcelulosa, la celulosa microcristalina y la polivinilpirrolidona reticulada micronizada.
ARP110104077A 2010-11-04 2011-11-03 Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit AR083693A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10190045 2010-11-04

Publications (1)

Publication Number Publication Date
AR083693A1 true AR083693A1 (es) 2013-03-13

Family

ID=43759428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104077A AR083693A1 (es) 2010-11-04 2011-11-03 Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit

Country Status (24)

Country Link
US (1) US9107836B2 (es)
EP (1) EP2635263B1 (es)
JP (1) JP5676005B2 (es)
KR (1) KR101579659B1 (es)
CN (2) CN103200935A (es)
AR (1) AR083693A1 (es)
BR (1) BR112013010704B8 (es)
CA (1) CA2815280C (es)
CL (1) CL2013001164A1 (es)
CR (1) CR20130181A (es)
EA (1) EA025649B1 (es)
EC (1) ECSP13012603A (es)
ES (1) ES2553279T3 (es)
IL (1) IL225780B (es)
MA (1) MA34643B1 (es)
MX (1) MX345650B (es)
MY (1) MY164729A (es)
NZ (1) NZ609529A (es)
PE (1) PE20140018A1 (es)
SG (1) SG190025A1 (es)
TW (1) TWI507192B (es)
UA (1) UA110117C2 (es)
WO (1) WO2012059447A1 (es)
ZA (1) ZA201302954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140007973A (ko) 2009-02-10 2014-01-20 아마린 파마, 인크. 고중성지방혈증 치료 방법
PT2978859T (pt) 2013-03-27 2018-10-04 Hoffmann La Roche Marcadores genéticos para previsão da capacidade de resposta à terapêutica
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JP6539661B2 (ja) 2013-12-19 2019-07-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 眼疾患の処置において使用するためのｃｅｔｐモデュレーター
MX2017000582A (es) 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
CN104434913A (zh) * 2014-12-20 2015-03-25 长沙佰顺生物科技有限公司 一种安塞曲匹药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7208465B2 (en) * 2000-11-03 2007-04-24 The Procter & Gamble Company Methods and compositions for improved fragrancing of a surface
ES2300628T3 (es) * 2002-12-20 2008-06-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa.
JP2006520810A (ja) 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
ES2377121T3 (es) 2003-03-17 2012-03-22 Japan Tobacco Inc. Composiciones farmacéuticas de inhibidores de CETP
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
CA2596240A1 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Fast-disintegrating microporous binder and process for making it
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process

Also Published As

Publication number Publication date
BR112013010704B8 (pt) 2021-11-09
EP2635263A1 (en) 2013-09-11
BR112013010704B1 (pt) 2021-06-29
AU2011325235A1 (en) 2013-05-02
EA025649B1 (ru) 2017-01-30
CN103200935A (zh) 2013-07-10
CR20130181A (es) 2013-05-29
CA2815280C (en) 2016-08-09
JP2013541572A (ja) 2013-11-14
KR20130083922A (ko) 2013-07-23
MA34643B1 (fr) 2013-11-02
SG190025A1 (en) 2013-06-28
AU2011325235B2 (en) 2016-01-21
KR101579659B1 (ko) 2015-12-22
NZ609529A (en) 2015-06-26
TW201300104A (zh) 2013-01-01
CL2013001164A1 (es) 2013-12-27
CN105833283A (zh) 2016-08-10
WO2012059447A1 (en) 2012-05-10
IL225780B (en) 2018-10-31
US20120115946A1 (en) 2012-05-10
UA110117C2 (uk) 2015-11-25
MY164729A (en) 2018-01-30
ZA201302954B (en) 2016-01-27
EA201390622A1 (ru) 2013-10-30
TWI507192B (zh) 2015-11-11
CA2815280A1 (en) 2012-05-10
MX2013004584A (es) 2013-05-17
ECSP13012603A (es) 2013-07-31
IL225780A0 (en) 2013-06-27
PE20140018A1 (es) 2014-01-31
JP5676005B2 (ja) 2015-02-25
BR112013010704A2 (pt) 2016-08-09
ES2553279T3 (es) 2015-12-07
AU2011325235A8 (en) 2016-02-04
US9107836B2 (en) 2015-08-18
EP2635263B1 (en) 2015-09-23
MX345650B (es) 2017-02-09

Similar Documents

Publication Publication Date Title
AR083693A1 (es) Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
CO6280440A2 (es) Derivados de aminobenzamida como agentes utiles para el control de parasito de animales
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112014011981A2 (pt) formulações farmacêuticas
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
ES2540151A1 (es) Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
CY1114480T1 (el) Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος
RU2011103476A (ru) Нифуртимокс для лечения болезней, вызванных трихомонадидами
MX2013006031A (es) Formulacion liposomal de dalcetrapib.

Legal Events

Date Code Title Description
FB Suspension of granting procedure